Evidence map›Paper›PMID 38565755›Full record

ArticleArchives of virology2024

miR-3188 inhibits hepatitis B virus transcription by targeting Bcl-2.

Shijie Wang, Ying Xie, Fufei Liu, Jianrong Wang, Yinghao Yang, Junxue Wang, Yongxiang Wang, Xiaofeng Hang

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Current perspectives of viral hepatitis.World journal of gastroenterology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Shijie Wang *Department of Infectious Diseases, Changzheng Hospital, Naval Medical University, Shanghai, China.
Ying Xie *Department of Infectious Diseases, Changzheng Hospital, Naval Medical University, Shanghai, China.
Fufei Liu *Department of Infectious Diseases, Changzheng Hospital, Naval Medical University, Shanghai, China.
Jianrong WangDepartment of Infectious Diseases, Changzheng Hospital, Naval Medical University, Shanghai, China.
Yinghao YangDepartment of Infectious Diseases, Changzheng Hospital, Naval Medical University, Shanghai, China.
Junxue WangDepartment of Infectious Diseases, Changzheng Hospital, Naval Medical University, Shanghai, China.
Yongxiang WangKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China. yongxiangwang@fudan.edu.cn.
Xiaofeng HangDepartment of Infectious Diseases, Changzheng Hospital, Naval Medical University, Shanghai, China. hangxfdoc@smmu.edu.cn.ORCID http://orcid.org/0000-0001-9115-9647
Shanghai Changzheng Hospital · CNShanghai Medical College of Fudan University · CN

Funding

Innovative clinical research project of Changzheng Hospital 2020YLCYJ-Y03National Major Science and Technology Projects of China 2012ZX20071002-001-005National Natural Science Foundation of China 31500141
6 · The paper itself

Abstract

Transcription of the covalently closed circular DNA (cccDNA) of hepatitis B virus (HBV) is subject to dual regulation by host factors and viral proteins. MicroRNAs (miRNAs) can regulate the expression of target genes at the post-transcriptional level. Systematic investigation of miRNA expression in HBV infection and the interaction between HBV and miRNAs may deepen our understanding of the transcription mechanisms of HBV cccDNA, thereby providing opportunities for intervention. miRNA sequencing and real-time quantitative PCR (qRT-PCR) were used to analyze miRNA expression after HBV infection of cultured cells. Clinical samples were analyzed for miRNAs and HBV transcription-related indicators, using qRT-PCR, enzyme-linked immunoassay (ELISA), and Western blot. miRNA mimics or inhibitors were used to study their effects on the HBV life cycle. The target genes of miR-3188 and their roles in HBV cccDNA transcription were also identified. The expression of 10 miRNAs, including miR-3188, which was significantly decreased after HBV infection, was measured in clinical samples from patients with chronic HBV infection. Overexpression of miR-3188 inhibited HBV transcription, whereas inhibition of miR-3188 expression promoted HBV transcription. Further investigation confirmed that miR-3188 inhibited HBV transcription by targeting Bcl-2. miR-3188 is a key miRNA that regulates HBV transcription by targeting the host protein Bcl-2. This observation provides insights into the regulation of cccDNA transcription and suggests new targets for anti-HBV treatment.

Indexed as

Hepatitis BHepatitis B, ChronicMicroRNAsDNA, CircularDNA, ViralHepatitis B virusHumansProto-Oncogene Proteins c-bcl-2Viral TranscriptionVirus ReplicationBCL2 protein, humanDNA, CircularDNA, ViralMicroRNAsMIRN3188 microRNA, humanProto-Oncogene Proteins c-bcl-2cccDNAHepatitis B virusMicroRNATranscription

Identifiers

PMID38565755
OpenAlexW4393404775

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.